![]() |
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Fusion gene ID: 23379 |
FusionGeneSummary for NAMPT_UBE2H |
![]() |
Fusion gene information | Fusion gene name: NAMPT_UBE2H | Fusion gene ID: 23379 | Hgene | Tgene | Gene symbol | NAMPT | UBE2H | Gene ID | 10135 | 7328 |
Gene name | nicotinamide phosphoribosyltransferase | ubiquitin conjugating enzyme E2 H | |
Synonyms | 1110035O14Rik|PBEF|PBEF1|VF|VISFATIN | E2-20K|GID3|UBC8|UBCH|UBCH2 | |
Cytomap | 7q22.3 | 7q32.2 | |
Type of gene | protein-coding | protein-coding | |
Description | nicotinamide phosphoribosyltransferaseNAmPRTasepre-B cell-enhancing factorpre-B-cell colony-enhancing factor 1 | ubiquitin-conjugating enzyme E2 H(E3-independent) E2 ubiquitin-conjugating enzyme HE2 ubiquitin-conjugating enzyme HGID complex subunit 3, UBC8 homologubiquitin carrier protein Hubiquitin conjugating enzyme E2Hubiquitin-conjugating enzyme E2-20Kubi | |
Modification date | 20180519 | 20180523 | |
UniProtAcc | P43490 | P62256 | |
Ensembl transtripts involved in fusion gene | ENST00000222553, ENST00000354289, ENST00000484527, | ENST00000355621, ENST00000473814, | |
Fusion gene scores | * DoF score | 3 X 3 X 1=9 | 7 X 8 X 4=224 |
# samples | 3 | 10 | |
** MAII score | log2(3/9*10)=1.73696559416621 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(10/224*10)=-1.16349873228288 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: NAMPT [Title/Abstract] AND UBE2H [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | NAMPT | GO:0008286 | insulin receptor signaling pathway | 17983582 |
Hgene | NAMPT | GO:0045944 | positive regulation of transcription by RNA polymerase II | 23001182 |
Hgene | NAMPT | GO:0051770 | positive regulation of nitric-oxide synthase biosynthetic process | 19727662 |
Hgene | NAMPT | GO:0060612 | adipose tissue development | 17983582 |
Tgene | UBE2H | GO:0070936 | protein K48-linked ubiquitination | 20061386 |
Tgene | UBE2H | GO:0070979 | protein K11-linked ubiquitination | 20061386 |
![]() (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChiTaRS3.1 | BF874906 | NAMPT | chr7 | 105906073 | - | UBE2H | chr7 | 129554703 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
intron-intron | ENST00000222553 | ENST00000355621 | NAMPT | chr7 | 105906073 | - | UBE2H | chr7 | 129554703 | + |
intron-intron | ENST00000222553 | ENST00000473814 | NAMPT | chr7 | 105906073 | - | UBE2H | chr7 | 129554703 | + |
intron-intron | ENST00000354289 | ENST00000355621 | NAMPT | chr7 | 105906073 | - | UBE2H | chr7 | 129554703 | + |
intron-intron | ENST00000354289 | ENST00000473814 | NAMPT | chr7 | 105906073 | - | UBE2H | chr7 | 129554703 | + |
intron-intron | ENST00000484527 | ENST00000355621 | NAMPT | chr7 | 105906073 | - | UBE2H | chr7 | 129554703 | + |
intron-intron | ENST00000484527 | ENST00000473814 | NAMPT | chr7 | 105906073 | - | UBE2H | chr7 | 129554703 | + |
Top |
FusionProtFeatures for NAMPT_UBE2H |
![]() |
Hgene | Tgene |
NAMPT | UBE2H |
Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamidemononucleotide, an intermediate in the biosynthesis of NAD. It isthe rate limiting component in the mammalian NAD biosynthesispathway. The secreted form behaves both as a cytokine withimmunomodulating properties and an adipokine with anti-diabeticproperties, it has no enzymatic activity, partly because of lackof activation by ATP, which has a low level in extracellular spaceand plasma. Plays a role in the modulation of circadian clockfunction. NAMPT-dependent oscillatory production of NAD regulatesoscillation of clock target gene expression by releasing the coreclock component: CLOCK-ARNTL/BMAL1 heterodimer from NAD-dependentSIRT1-mediated suppression (By similarity).{ECO:0000250|UniProtKB:Q99KQ4, ECO:0000269|PubMed:24130902}. | Accepts ubiquitin from the E1 complex and catalyzes itscovalent attachment to other proteins. In vitro catalyzes 'Lys-11'- and 'Lys-48'-linked polyubiquitination. Capable, in vitro, toubiquitinate histone H2A. {ECO:0000269|PubMed:20061386,ECO:0000269|PubMed:8132613}. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for NAMPT_UBE2H |
![]() (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for NAMPT_UBE2H |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for NAMPT_UBE2H |
![]() (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for NAMPT_UBE2H |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | NAMPT | C0009319 | Colitis | 1 | CTD_human |
Hgene | NAMPT | C0009404 | Colorectal Neoplasms | 1 | CTD_human |
Hgene | NAMPT | C0028754 | Obesity | 1 | CTD_human |
Hgene | NAMPT | C0162820 | Dermatitis, Allergic Contact | 1 | CTD_human |
Tgene | UBE2H | C0004352 | Autistic Disorder | 1 | CTD_human |
Tgene | UBE2H | C0032460 | Polycystic Ovary Syndrome | 1 | CTD_human |